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Department of Justice win
On Wednesday, October 21, 2020 the U.S. Department of Justice announced a global resolution of its criminal and civil investigations into the opioid manufacturer Purdue Pharma LP (Purdue), and a civil resolution of its civil investigation into individual shareholders from the Sackler family.  The resolutions with Purdue are subject to the approval of the bankruptcy court.  
Deputy Attorney General Jeffrey Rosen said:

“The abuse and diversion of prescription opioids has contributed to a national tragedy of addiction and deaths, in addition to those caused by illicit street opioids. With criminal guilty pleas, a federal settlement of more than $8 billion, and the dissolution of a company and repurposing its assets entirely for the public’s benefit, the resolution in today’s announcement re-affirms that the Department of Justice will not relent in its multi-pronged efforts to combat the opioids crisis. Today’s resolution is the result of years of hard work by the FBI and its partners to combat the opioid crisis in the U.S.”

 Steven M. D’Antuono, Assistant Director in Charge of the FBI Washington Field Office said:

 “Purdue, through greed and violation of the law, prioritized money over the health and well-being of patients.  The FBI remains committed to holding companies accountable for their illegal and inexcusable activity and to seeking justice, on behalf of the victims, for those who contributed to the opioid crisis.”

Guilty 
Purdue Pharma has agreed to plead guilty in federal court in New Jersey to a three-count felony information charging it with:
* One count of dual-object conspiracy to defraud the United States and to violate the Food, Drug, and Cosmetic Act,
* Two counts of conspiracy to violate the Federal Anti-Kickback Statute.  

Criminal fine of $3.544 billion plus “2 billion in criminal forfeiture
The criminal resolution includes the largest penalties ever levied against a pharmaceutical manufacturer, including a criminal fine of $3.544 billion and an additional $2 billion in criminal forfeiture.  
For the $2 billion forfeiture, the company will pay $225 million on the effective date of the bankruptcy, and, as further explained below, the department is willing to credit the value conferred by the company to State and local governments under the department’s anti-piling on and coordination policy. 

Federal False Claims Act: Purdue settled civil liability of $2.8 billion
Purdue has also agreed to a civil settlement in the amount of $2.8 billion to resolve its civil liability under the False Claims Act.  Separately, the Sackler family has agreed to pay $225 million in damages to resolve its civil False Claims Act liability.
The resolutions do not include the criminal release of any individuals, including members of the Sackler family, nor are any of the company’s executives or employees receiving civil releases.
While the global resolution with the company is subject to approval by the bankruptcy court in the Southern District of New York, one important condition in the resolution is that the company would cease to operate in its current form. 

In the public interest
Purdue Pharma will no longer exist  and will emerge from bankruptcy as a Public Benefit Company (PBC) owned by a trust or similar entity designed for the benefit of the American public, to function entirely in the public interest. The PBC must to deliver legitimate prescription drugs in a manner as safe as possible, but it will aim to donate, or provide steep discounts for, life-saving overdose rescue drugs and medically assisted treatment medications to communities. The proceeds of the trust will be directed toward State and local opioid abatement program. Based on the value that would be conferred to State and local governments through the PBC, the department is willing to credit up to $1.775 billion against the agreed $2 billion forfeiture amount. The U.S.D.o.J. will work with the creditor groups in the bankruptcy in charting the path forward for this PBC so that its public health goals can be best accomplished.

Criminal Pleas
As part of the plea, Purdue Pharma will admit that from May 2007 through at least March 2017, it conspired to defraud the United States by impeding the lawful function of the DEA by representing to the DEA that Purdue maintained an effective anti-diversion program when, in fact, Purdue continued to market its opioid products to more than 100 health care providers whom the company had good reason to believe were diverting opioids and by reporting misleading information to the DEA to boost Purdue’s manufacturing quotas. 

 Reporting misleading information
The misleading information comprised prescription data that included prescriptions written by doctors that Purdue had good reason to believe were engaged in diversion. 

Aiding and abetting violations of U.S. Food, Drug & Cosmetic Act
The conspiracy also involved aiding and abetting violations of the Food, Drug, and Cosmetic Act by facilitating the dispensing of its opioid products, including OxyContin, without a legitimate medical purpose, and thus without lawful prescriptions.

Conspiracy to violate U.S. Anti-kickback Statute
In addition, Purdue will admit to conspiring to violate the Federal Anti-Kickback Statute.  Between June 2009 and March 2017, Purdue made payments to two doctors through Purdue’s doctor speaker program to induce those doctors to write more prescriptions of Purdue’s opioid products.  Similarly, from approximately April 2016 through December 2016, Purdue made payments to Practice Fusion Inc., an electronic health records company, in exchange for referring, recommending, and arranging for the ordering of Purdue’s extended release opioid products – OxyContin, Butrans, and Hysingla.

The Civil Settlements by Purdue Pharma
The department’s civil settlements resolve the United States’ claims as to both Purdue and its individual shareholders, members of the Sackler family. The civil settlement with Purdue provides the United States with an allowed, unsubordinated, general unsecured bankruptcy claim for recovery of $2.8 billion.  
 
Causing false claims submissions to Medicare, Medicaid, & TRICARE
This settlement resolves allegations that from 2010 to 2018, Purdue caused false claims to be submitted to federal health care programs, specifically Medicare, Medicaid, TRICARE, the Federal Employees Health Benefits Program, and the Indian Health Service.  

The government alleged that Purdue promoted its opioid drugs to health care providers it knew were prescribing opioids for uses that were unsafe, ineffective, and medically unnecessary, and that often led to abuse and diversion.  For example, Purdue learned that one doctor was known by patients as “the Candyman” and was prescribing “crazy dosing of OxyContin,” yet Purdue had sales representatives meet with the doctor more than 300 times.  

Three different kickback schemes used by Purdue Pharma
This settlement also resolves the government’s allegations that Purdue engaged in three different kickback schemes to induce prescriptions of its opioids in three stages:  
*Purdue paid certain doctors ostensibly to provide educational talks to other health care professionals and serve as consultants, but in reality to induce them to prescribe more OxyContin.  
*Purdue paid kickbacks to Practice Fusion, as described above.  
*Purdue entered into contracts with certain specialty pharmacies to fill prescriptions for Purdue’s opioid drugs that other pharmacies had rejected as potentially lacking medical necessity.

Civil settlement by the Named SACKLER Family
Under a separate civil settlement, individual members of the Sackler family will pay the United States $225 million arising from the alleged conduct of Dr. Richard Sackler, David Sackler, Mortimer D.A. Sackler, Dr. Kathe Sackler, and Jonathan Sackler (the Named Sacklers).  This settlement resolves allegations that, in 2012, the Named Sacklers knew that the legitimate market for Purdue’s opioids had contracted.  Nevertheless, they requested that Purdue executives recapture lost sales and increase Purdue’s share of the opioid market.  The Named Sacklers then approved a new marketing program beginning in 2013 called “Evolve to Excellence,” through which Purdue sales representatives intensified their marketing of OxyContin to extreme, high-volume prescribers who were already writing “25 times as many OxyContin scripts” as their peers, causing health care providers to prescribe opioids for uses that were unsafe, ineffective, and medically unnecessary, and that often led to abuse and diversion. 

Purdue transferred assets to Names Sacklers to hinder future creditors
The civil settlement also resolves the government’s allegations between 
2008 and 2018, at the Named Sacklers’ request, Purdue transferred assets into Sackler family holding companies and trusts that were made to hinder future creditors, and/or were otherwise voidable as fraudulent transfers. The resolutions of 21.10.20 do not resolve claims that states may have against Purdue or members of the Sackler family, nor does it impede the debtors’ ability to recover any fraudulent transfers. This U.S.D.o.J. announcement was made by Deputy Attorney General Jeffrey A. Rosen and others.

Purdue Bankruptcy
The Purdue bankruptcy matter is being handled by the U.S. Attorney’s Office for the Southern District of New York and the Civil Division’s Commercial Litigation Branch, Corporate/Finance Section. Except to the extent of Purdue’s admissions as part of its criminal resolution, the claims resolved by the civil settlements are allegations only. There has been no determination of liability in the civil matters. 

Comment on Purdue Investigation
This case should be a lesson to other companies in the medical industry, in which there are many such frauds committed by executive officers, aided and abetted by sharp-eyed lawyers who create loopholes in the law without conscience, care or professional ethics- their only care is for money for their clients and fat fees for themselves. Such frauds are despicable and as heart-breaking as the Madoff Ponzi fraud of $65, 000,000,000 ($65 billion spent on himself and family instead of investing clients’ money). Despite Madoff securities investment which was a slush fund for Madoff and his family, the investment industry in rich countries (US, UK, EU, eg) and riddled with con-men and con-women whose only objective is to grab more money for themselves, regardless of how many hard-working lives they destroy or disrupt.  Enron was a company whose management misrepresented the company, and committed fraud. They were caught-out by computerization. Yet computerization is the means by which Madoff burgled investors of a sum totalling $65 Billion- because we trusted the computer printouts he sent to thousands of intelligent investors, yet robbed them of $65 Billion. I see his three floors of the High-rise Manhattan building he rented as office space as carefully planned to impress any inspectors or potential clients. Madoff must have been a cold-blooded psychopath to swindle his own friends, churches, charities and most importantly, the very secret swathe of investors in Europe, including the United Kingdom, who never even raised their hand to admit they lost billions and billions of pounds stolen by Bernard Madoff. Madoff is the biggest and most frightening conman I have ever known as a case-study and even remotely, he sends shivers down my spine-as does Purdue Pharma.
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